Nuveen’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Nuveen’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-222,679	Closed	-$23.9M	–	3358
2023 Q1	$23.9M	Sell	222,679 -45,940	-17%	-$5.29M	0.01%	920
2022 Q4	$29.5M	Sell	268,619 -66,061	-20%	-$4.28M	0.01%	806
2022 Q3	$19.7M	Buy	334,680 +233,507	+231%	+$10.7M	0.01%	1018
2022 Q2	$2.86M	Sell	101,173 -19,662	-16%	-$570K	﹤0.01%	2249
2022 Q1	$5.14M	Sell	120,835 -7,069	-6%	-$279K	﹤0.01%	2044
2021 Q4	$4M	Buy	127,904 +87,973	+220%	+$2.75M	﹤0.01%	2245
2021 Q3	$1.04M	Buy	39,931 +7,558	+23%	+$178K	﹤0.01%	2974
2021 Q2	$795K	Buy	+32,373	New	+$722K	﹤0.01%	3086

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Nuveen's RXDX Position: Q2 2023 in Review

Nuveen sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 222,679 shares — an estimated $23.9M sold.

Nuveen first reported a position in RXDX in Q2 2021 and held it in 8 quarters. The position peaked at $29.5M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Nuveen reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Nuveen sold 222,679 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $23.9M.
Nuveen first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Nuveen's Prometheus Biosciences, Inc. Common Stock position peaked at $29.5M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Nuveen's 13F filing for Q2 2023, filed 14 Aug 2023.